⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8463116 | 0.71 | — | — | |
| 1,4-Dichlorobenzene SCHEMBL11243685 | 0.71 | — | — | |
| 1,4-Dichlorobenzene SCHEMBL5191 | 0.71 | — | — | |
| SCHEMBL4049600 | 0.69 | MEN1 (0.38) | — | |
| SCHEMBL4044183 | 0.69 | AHR (0.43) | — | |
| SCHEMBL7223845 | 0.69 | — | — | |
| 1,4-Dichlorobenzene SCHEMBL27640906 | 0.68 | LMNA (0.73) | — | |
| SCHEMBL3246739 | 0.67 | — | — | |
| SCHEMBL953874 | 0.67 | — | — | |
| 1,4-Dichlorobenzene SCHEMBL15668734 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081347-A1 | FUNCTIONALIZED AZABORINE COMPOUNDS AND AZABORINE-CONTAINING BIARYLCARBOXAMIDES, AND COMPOSITIONS AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| WO-2015160688-A1 | FUNCTIONALIZED AZABORINE COMPOUNDS AND AZABORINE-CONTAINING BIARYLCARBOXAMIDES, AND COMPOSITIONS AND METHODS THEREOF | THE TRUSTEES OF BOSTON COLLEGE (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2009075691-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1937677-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | Arcadia Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008048648-A2 | CB1-MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| WO-2007047737-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1709046-A1 | P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073232-A1 | P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
| US-6593480-B2 | Obesity, hyperglycemia | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| WO-2002070507-A2 | GLYCORTICOID RECEPTOR ANTAGONISTS FOR TREATMENT OF DIABETES | ABBOTT LABORATORIES (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | KARO BIO AB (SE) | 2001-11-15 | — | — | US | disclosed |